

## Hawaii ALS and Neuromuscular Center & Hawaii Center for Rare Neurological Diseases 1 of 30 US sites selected for **Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) HYbISCUE Study**




According to [Takeda](#), CIDP is a rare, acquired, immune-mediated neuromuscular disorder. It is typically characterized by progressive, symmetric symptoms such as weakness, tingling or loss of feeling in distal and proximal limbs, loss of reflexes and difficulty walking. CIDP is often misdiagnosed. The role of IG therapy as maintenance treatment in CIDP has been well-established and is the guidelines-based standard of care for this complex and heterogeneous condition. However, IVIG treatment that can be challenging for patients such as long treatment duration

associated with high IG volumes, potential for venous access challenges, and infusion setting limitations.

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or Self-Administered after Appropriate Training. FDA Approval is based on Phase 3 ADVANCE-CIDP 1 Study Demonstrating a Statistically Significant Difference in Relapse Rate in Favor of HYQVIA Versus Placebo at 6 Months.

The main aims of HYbISCUE Study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and activity is impacted and learn about their CIDP signs and symptoms.

For more information, call (808) 564-6141 or [NIH Info](#).



*Our Hawaii patients, caregivers, families, neurologists & researchers are honored to contribute to the development of Novel Neuromuscular Therapy” [Natalia Gonzalez, MD](#), Director of [Hawaii ALS and Neuromuscular Center](#) and Sub investigator [Neuromuscular Research Unit](#), who is dual fellowship trained in Neuromuscular and*

*Neuroimmunology and [Kore Kai Liow, MD](#), Neurologist & Principal Investigator, [Center for Rare Neurological Disorders](#) Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai`i John Burns School of Medicine.*

***Dedicated Neuromuscular Research Hotline (808) 564-6141***



CLINICAL TRIALS